SCHEMBL1240342

SCHEMBL1240342

Oc1c(CN2CCOCC2)cc(Cl)c2cccnc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 3/20 1.00
RAB9A P51151 9/20 0.82
L3MBTL1 Q9Y468 9/20 0.82
NPC1 O15118 7/20 0.82
PAX8 Q06710 1/20 0.82
HTT P42858 13/20 0.73
MAPT P10636 11/20 0.73
SMN1; SMN2 Q16637 11/20 0.73
LMNA P02545 10/20 0.73
KDM4E B2RXH2 10/20 0.73
TDP1 Q9NUW8 7/20 0.73
ALDH1A1 P00352 5/20 0.73
MPI P34949 3/20 0.73
NPSR1 Q6W5P4 10/20 0.69
KMT2A Q03164 3/20 0.69
HSP90AA1 P07900 2/20 0.69
MAPK1 P28482 2/20 0.69
USP2 O75604 1/20 0.69
NOD2 Q9HC29 1/20 0.69
TP53 P04637 4/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12530781 0.99 METAP2 (0.98) METAP2RAB9AL3MBTL1NPC1PAX8
SCHEMBL11955292 0.91 METAP2 (0.88) METAP2RAB9AL3MBTL1NPC1PAX8
SCHEMBL27253776 0.90 L3MBTL1 (1.00) METAP2RAB9AL3MBTL1NPC1PAX8
SCHEMBL31452761 0.89 METAP2 (0.97) METAP2RAB9AL3MBTL1NPC1PAX8
SCHEMBL1240789 0.89 L3MBTL1 (0.80) METAP2RAB9AL3MBTL1NPC1PAX8
SCHEMBL9996355 0.88 METAP2 (1.00) METAP2RAB9AL3MBTL1NPC1PAX8
SCHEMBL2312166 0.85 METAP2 (1.00) METAP2RAB9AL3MBTL1NPC1PAX8
SCHEMBL12530869 0.84 METAP2 (0.73) METAP2RAB9AL3MBTL1NPC1PAX8
SCHEMBL18719791 0.83 METAP2 (0.75) METAP2RAB9AL3MBTL1NPC1PAX8
SCHEMBL12905940 0.82 METAP2 (0.70) METAP2RAB9AL3MBTL1NPC1PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350012-B1 QUINOLINE COMPOUNDS AS INHIBITORS OF ANGIOGENESIS, HUMAN METHIONINE AMINOPEPTIDASE, AND SIRT1, AND METHODS OF TREATING DISORDERS UNIV JOHNS HOPKINS (US) 2017-06-28 EP disclosed
US-9012899-B2 Electroluminescent metal complexes with nucleophilic carbene ligands BASF SE (DE) 2015-04-21 US disclosed
US-8906937-B2 Flavivirus inhibitors and methods of their use GEORGETOWN UNIVERSITY (US) 2014-12-09 US disclosed
US-8906937-B2 Flavivirus inhibitors and methods of their use GEORGETOWN UNIVERSITY (US) 2014-12-09 US disclosed
US-8729097-B2 Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders THE JOHNS HOPKINS UNIVERSITY (US) 2014-05-20 US disclosed
US-20140038962-A1 Flavivirus Inhibitors and Methods of Their Use GEORGETOWN UNIVERSITY (US) 2014-02-06 US disclosed
US-20140038962-A1 Flavivirus Inhibitors and Methods of Their Use GEORGETOWN UNIVERSITY (US) 2014-02-06 US disclosed
US-20130292660-A1 ELECTROLUMINESCENT METAL COMPLEXES WITH NUCLEOPHILIC CARBENE LIGANDS BASF SE (DE) 2013-11-07 US disclosed
US-8563580-B2 Flavivirus inhibitors and methods for their use GEORGETOWN UNIVERSITY (US) 2013-10-22 US disclosed
US-8563580-B2 Flavivirus inhibitors and methods for their use GEORGETOWN UNIVERSITY (US) 2013-10-22 US disclosed
US-20110224207-A1 FLAVIVIRUS INHIBITORS AND METHODS FOR THEIR USE GEORGETOWN UNIVERSITY (US) 2011-09-15 US disclosed
EP-2350012-A2 QUINOLINE COMPOUNDS AS INHIBITORS OF ANGIOGENESIS, HUMAN METHIONINE AMINOPEPTIDASE, AND SIRT1, AND METHODS OF TREATING DISORDERS The Johns Hopkins University (US) 2011-08-03 EP disclosed
US-20110114922-A1 Electroluminescent Metal Complexes with Nucleophilic Carbene Ligands UDC IRELAND LIMITED (IE) 2011-05-19 US disclosed
WO-2011020886-A1 NOVEL QUINOLINE-HEPCIDINE ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2011-02-24 WO disclosed
WO-2010042163-A2 QUINOLINE COMPOUNDS AS INHIBITORS OF ANGIOGENESIS, HUMAN METHIONINE AMINOPEPTIDASE, AND SIRT1, AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2010-04-15 WO disclosed
WO-2010039538-A2 FLAVIVIRUS INHIBITORS AND METHODS FOR THEIR USE GEORGETOWN UNIVERSITY (US) 2010-04-08 WO disclosed
EP-2080796-A1 Electroluminescent metal complexes with nucleophilic carbene ligands Ciba Holding Inc. (CH) 2009-07-22 EP disclosed
CN-101087863-A Electroluminescent metal complexes with nucleophilic carbene ligands CIBA SC HOLDING AG (CH) 2007-12-12 CN disclosed
EP-1841834-A1 ELECTROLUMINESCENT METAL COMPLEXES WITH NUCLEOPHILIC CARBENE LIGANDS Ciba Specialty Chemicals Holding Inc. (CH) 2007-10-10 EP disclosed
WO-2006067074-A1 ELECTROLUMINESCENT METAL COMPLEXES WITH NUCLEOPHILIC CARBENE LIGANDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224207-A1 FLAVIVIRUS INHIBITORS AND METHODS FOR THEIR USE SERPINB1, SPINT2, MME METAP2 71/4885RAB9A 2084/4885L3MBTL1 1524/4885
US-20110114922-A1 Electroluminescent Metal Complexes with Nucleophilic Carbene Ligands OCIAD1, OCIAD2, C1S METAP2 4435/4885RAB9A 3166/4885L3MBTL1 96/4885
US-20140038962-A1 Flavivirus Inhibitors and Methods of Their Use SERPINB1, SPINT2, MME METAP2 57/4885RAB9A 2277/4885L3MBTL1 1446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.